List Title | APhA DrugInfoLine

Drug Interactions Corner

SORT BY: Most Recent Most Viewed

November 10, 2015

PPI–clopidogrel interaction a concern after stent placement

READ

PREVIEW
Concomitant use of proton pump inhibitors (PPIs) and clopidogrel in patients with diabetes who received a drug-eluting stent was associated with an increased risk of acute coronary syndrome (ACS...
July 28, 2015

Serious drug interactions increase with use of multiple guidelines

READ

PREVIEW
Serious drug interactions may occur if medications recommended by evidence-based guidelines to manage varying chronic conditions are used concurrently, according to a systematic review of 12...
April 7, 2015

Statins and clarithromycin: Role of non-CYP3A4 interactions

READ

PREVIEW
Results of a large population-based cohort study suggest that there may be a drug–drug interaction between clarithromycin, a potent cytochrome P450 3A4 (CYP3A4) inhibitor, and statins not...
January 7, 2015

Vancomycin nephrotoxicity increased with piperacillin–tazobactam

READ

PREVIEW
Results from several studies suggest that the incidence of vancomycin-associated nephrotoxicity is increased in patients who are receiving concurrent piperacillin–tazobactam.
December 2, 2014

Apixaban outperforms warfarin in patients taking amiodarone

READ

PREVIEW
An exploratory posthoc analysis of the ARISTOTLE trial concluded that in patients with atrial fibrillation (AF) who require amiodarone therapy, anticoagulation with apixaban (Eliquis—Bristol-...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.